The ICIs approved for the treatment of different cancers include agents that target the programmed cell death protein 1 receptor (PD-1: nivolumab, pembrolizumab, cemiplimab), programmed death-ligand 1 (PD-L1: atezolizumab, avelumab, durvalumab), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4: ipilimumab, tremelimumab) [2,3]. This evidence concerns the gene PDCD1 and cancer.